Shopping Cart 0
Cart Subtotal
USD 0

Novartis AG (NOVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG (NOVN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 13

List of Figures 19

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Novartis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25

Novartis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27

Novartis AG, Pharmaceuticals & Healthcare, Deal Details 62

Asset Purchase 62

Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 62

Fougera Pharma Acquires US Rights to Veregen from Medigene 63

Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 64

Sandoz Acquires Product Portfolio of Euro-Pharm International Canada 66

Novartis Acquires Rights to Interleukin-17 from Ensemble Therapeutics 67

Novartis Acquires Rights of PF-06438179 from Pfizer 68

Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 69

Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 70

Teva Pharma May Divest its Assets 71

Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 73

Novartis Pharma Acquires Immunotherapy Manufacturing Facility From Dendreon For USD 43 Million 75

SensoMotoric Sells Ophthalmic Division To Alcon Labs 76

Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 77

Venture Financing 78

Galera Therapeutics Raises USD70 Million in Series C Venture Financing 78

Coda Biotherapeutics Raises USD19 Million in Series A Financing 80

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 81

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 83

Akouos Raises USD50 Million in Series A Financing 85

Enterprise Therapeutics Raises USD41.1 Million in Series B Venture Financing 87

Oculis Raises USD20.51 Million in Series B Financing 89

Expansion Therapeutics Raises USD55.3 Million in Series A Financing 91

Semma Therapeutics Raises USD114 Million in Series B Financing 93

Perlara Raises USD7.4 Million in Venture Financing 95

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 96

ImaginAb Raises USD7.7 Million in Venture Financing 98

Rani Therapeutics Raises USD39 Million in Series D Financing 99

Homology Medicines Raises USD83.5 Million in Series B Financing 101

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 103

NeuroVia Raises USD14 Million in Series A Financing 105

E-scape Bio Raises Additional USD8 Million in Series A Financing 106

Anaeropharma Science Raises USD13.2 Million in Venture Financing 108

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 109

ONL Therapeutics Raises USD4.2 Million in Series A Venture Financing 111

Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 112

Cavion Raises USD26 Million in Series A Financing 114

Inflazome Raises USD17 Million in Series A Financing 115

Rox Medical Raises USD40 Million in Series E Financing 116

Annexon Biosciences Raises USD44 Million in Series B Financing 117

IFM Therapeutics Raises USD27 Million in Series A Financing Round 118

F2G Raises USD60 Million in Venture Financing 119

Blade Therapeutics Raises USD27 Million in Series B Financing 121

Caribou Biosciences Raises USD30 Million in Series B Financing Round 123

Ideaya Biosciences Raises USD46 Million in Series A Financing 125

Rani Therapeutics Raises Funds in Financing 127

Galera Therapeutics Raises Additional USD5 Million in Series B Financing 129

Adicet Bio Raises USD51 Million in Series A Financing Round 130

C4 Therapeutics Raises USD73 Million in Series A Financing Round 131

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 132

Galera Therapeutics Raises USD37 Million in Series B Financing 134

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 135

Intellia Therapeutics Raises USD70 Million in Series B Financing 137

Merus Raises USD46.4 Million in First Tranche of Series C Financing 139

Encore Vision Raises USD2.5 Million in Series C Financing 141

E-scape Bio Raises USD55 Million in Series A Financing 142

Ra Pharma Raises USD58.5 Million in Series B Financing 144

Advanced Accelerator Applications Raises USD26 Million in Venture Financing 146

Kanyos Bio Raises USD16 Million in Venture Financing 147

Arcus Biosciences Raises USD50 Million in Series A Financing 148

Rani Therapeutics Raises USD25 Million in Series C Venture Financing 150

Innocrin Pharma Raises USD28 Million in Series D Financing 151

Nabriva Therapeutics Raises USD120 Million in Series B Financing 152

Caribou Biosciences Raises USD11 Million in Series A Financing 154

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 156

Neurovance Raises Additional USD5.5 Million in Venture Financing 157

Macrolide Pharma Raises USD22 Million in Series A Financing 158

Merganser Biotech Raises USD28 Million in Series A Financing 159

Vaxin Raises USD16 Million in Venture Financing 160

Surface Oncology Raises USD35 Million in Series A Financing 161

Annexon Bioscience Raises USD34 Million in Series A-1 Venture Financing 163

Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 164

Ziarco Raises USD33 Million in Series B Venture Financing 165

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 166

Quartet Medicine Raises USD17 Million in Series A Venture Financing 168

Innocrin Pharma Raises Funds through Venture Financing 169

Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 170

Viamet Pharma Raises USD60 Million in Series D Venture Financing 172

Raze Therapeutics Raises USD24 Million in Series A Venture Financing 173

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 175

Encore Vision Raises USD1.7 Million in Venture Financing 176

Neurovance Raises Additional USD4 Million in Venture Financing 177

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 178

Sorbent Therapeutics Raises USD6.5 Million In First Tranche Of Series D Financing 179

ImaginAb Raises USD21 Million in Series B Venture Financing 180

Anokion Raises USD 37.5 Million In Series A Venture financing 181

Aerpio Therapeutics Raises USD 22 Million In Venture Financing 182

Spinifex Pharma Raises USD6.2 Million in Venture Financing 184

Spinifex Pharma Raises USD 45 Million In Series C Financing 185

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 187

Thesan Pharma Raises USD 49 Million In Series B Venture Financing 188

Covagen Raises USD 50.3 Million In Series B Financing 189

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 191

Encore Vision Secures USD5 Million in Venture Funding 192

Aileron Therapeutics Raises USD 30 Million In Series E Financing 193

Aerpio Therapeutics Raises USD 9 Million In Extended Series A Financing 195

Merus Raises USD 42 Million In Extended Series B Financing 197

Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 199

Akebia Therapeutics Raises USD 41 Million In Series C Financing 201

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 202

Effector Therapeutics Raises USD 45 Million In Series A Financing 203

Tokai Pharma Raises USD 35.5 Million In Series E Financing 205

Neurovance Raises USD 6 Million In Series A1 Financing 206

GenSight Biologics Raises USD 41.6 Million In Series A Financing 208

Catalyst Biosciences Secures USD5.07 Million in Venture Funding 210

CoStim Pharma Raises USD 10 Million In Venture Financing 212

Aileron Raises USD 12 Million In Extended Series D Financing 213

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 215

Galera Therapeutics Raises USD 11 Million In Series A Financing 217

Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 218

Thesan Pharma Raises Additional USD 12 Million In Series A Financing 219

Qurient Raises USD 4 Million In Venture Financing 220

Selexys Pharma Raises USD 23 Million In Series A Financing 221

F2G Raises USD 30 Million In Venture Financing 222

Aerpio Therapeutics Raises USD 27 Million In Series A Financing 223

PharmAbcine Raises USD 3.5 Million In Series B Financing 224

Ra Pharma Raises USD 8.6 Million In Second Tranche Of Series A Financing 225

Celladon Raises Additional USD 10 Million In Series D Financing 226

BioRelix Raises USD 0.27 Million In Venture Financing 228

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 229

Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 230

AMP Therapeutics Raises Funds Through Series A Financing 231

Private Equity 232

Samara Capital Partners Acquires Anti-Infective Brands from Novartis 232

Gamida Cell Raises USD40 Million in Private Financing 233

Ampersand Capital Partners and 1315 Capital Acquires Genoptix 235

dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 236

Partnerships 237

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 237

Pfizer Enters into Co-Development Agreement with Novartis 238

Global Antibiotic Research & Development Partnership Enters into Partnership with Novartis 239

Novartis and Mundipharma Enter into Agreement 240

Novartis and Albumedix Enter into Agreement 241

Pear Therapeutics Enters into Agreement with Sandoz 242

Novartis to Enter into Agreement with Wyss Institute for Biologically Inspired Engineering at Harvard 243

Pear Therapeutics Enters into Agreement with Novartis 244

Novartis and Bill & Melinda Gates Foundation Enter into Partnership 245

Sandoz International Enters into Agreement with Biocon 246

Homology Medicines Enters into Agreement with Novartis 247

Novartis Enters into Agreement with University of California 248

Helsinn Therapeutics Enters into Co-Promotion Agreement with Novartis 249

Cipla and Novartis May Enter into Co-Marketing Agreement 250

Oxford BioMedica Enters into Agreement with Novartis 251

Bristol-Myers Squibb Enters into Partnership with Novartis 252

Allergan Enters into Agreement with Novartis 253

Perthera Enters into Agreement with Novartis 254

TARGET PharmaSolutions Enters into Agreement with Novartis 255

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 256

Protagen Enters into Agreement with Novartis Pharma 258

Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 259

Rovi Enters into Co-Marketing Agreement with Novartis for Neparvis 260

Cerulean Pharma Enters into Partnership with Novartis 261

Perlara Enters into Partnership with Novartis 262

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 263

Cure Forward Partners with Novartis Pharma 264

Novartis Expands its Agreement with Medicines for Malaria Venture 265

Novartis Pharma Enters into Agreement with Eisai 266

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 267

Cigna Enters into Contract with Novartis 268

MedinCell Enters into Agreement with Sandoz International 269

Radius Health Partners with Novartis Pharma for RAD1901 270

NeoBiocon Enters into Agreement with Novartis 271

Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 272

Amgen Expands its Co-Development Agreement with Novartis 273

Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 274

Sosei Plans to Enter into Agreement with Novartis 275

Rani Therapeutics Enters into Agreement with Novartis 276

PaxVax Enters into Distribution Agreement with Novartis 277

Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 278

Semma Therapeutics Enters into Agreement with Novartis 279

Novartis Enters into Co-Development Agreement with Department of Science & Technology 280

PeptiDream Expands Drug Discovery Agreement with Novartis 281

BioLineRx Enters into Agreement with Novartis Pharma 282

Rega Institute for Medical Research, Centre for Drug Design and Discovery, KRICT Enters into Partnership with Novartis 283

Novartis Enters into Licensing Agreement with Ligand Pharma 334

Novartis AG - Key Competitors 506

Novartis AG - Key Employees 507

Novartis AG - Locations And Subsidiaries 509

Head Office 509

Other Locations & Subsidiaries 509

Recent Developments 527

Strategy And Business Planning 527

Oct 30, 2018: Novartis and Pfizer partner to advance NASH therapy 527

Oct 04, 2018: Novartis licences anti-infective candidates to Boston Pharmaceuticals 528

Sep 28, 2018: Novartis signs Chinese manufacturing deal with Cellular Biomedicines for Kymriah 529

Sep 25, 2018: Novartis to cut more than 2000 jobs in Switzerland and UK 530

Sep 25, 2018: Novartis proposes to exit Grimsby UK site by end of 2020 as part of global manufacturing network transformation 531

Sep 11, 2018: Nova Medical Centers opens occupational medicine clinic in El Paso, Texas 532

Sep 06, 2018: Novartis to divest select Sandoz US portfolio to Aurobindo for $900m 533

Jul 02, 2018: Novartis plans to spin-off eye care unit into standalone entity 534

Oct 16, 2017: Novartis to Shut Broomfield Generics Manufacturing Unit, Eliminate 450 Jobs 535

Financial Announcements 536

Oct 18, 2018: Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth 536

Jul 18, 2018: Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company 541

Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 546

Jan 24, 2018: Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase 550

Oct 24, 2017: Novartis delivered growth on top and bottom line in all divisions in Q3 558

Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 563

Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 568

Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 572

Corporate Communications 578

Aug 14, 2018: Novartis names Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer 578

May 16, 2018: Novartis announces changes to the Executive Committee 579

Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 580

Mar 19, 2018: Novartis Foundation joins Global Partnership for Zero Leprosy 581

Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 582

Dec 15, 2017: Novartis announces Oncology head to retire 583


List Of Figure

List of Figures

Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21

Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25


List Of Table

List of Tables

Novartis AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Novartis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Novartis AG, Deals By Therapy Area, 2012 to YTD 2018 23

Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25

Novartis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27

Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 62

Fougera Pharma Acquires US Rights to Veregen from Medigene 63

Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 64

Sandoz Acquires Product Portfolio of Euro-Pharm International Canada 66

Novartis Acquires Rights to Interleukin-17 from Ensemble Therapeutics 67

Novartis Acquires Rights of PF-06438179 from Pfizer 68

Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 69

Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 70

Teva Pharma May Divest its Assets 71

Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 73

Novartis Pharma Acquires Immunotherapy Manufacturing Facility From Dendreon For USD 43 Million 75

SensoMotoric Sells Ophthalmic Division To Alcon Labs 76

Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 77

Galera Therapeutics Raises USD70 Million in Series C Venture Financing 78

Coda Biotherapeutics Raises USD19 Million in Series A Financing 80

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 81

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 83

Akouos Raises USD50 Million in Series A Financing 85

Enterprise Therapeutics Raises USD41.1 Million in Series B Venture Financing 87

Oculis Raises USD20.51 Million in Series B Financing 89

Expansion Therapeutics Raises USD55.3 Million in Series A Financing 91

Semma Therapeutics Raises USD114 Million in Series B Financing 93

Perlara Raises USD7.4 Million in Venture Financing 95

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 96

ImaginAb Raises USD7.7 Million in Venture Financing 98

Rani Therapeutics Raises USD39 Million in Series D Financing 99

Homology Medicines Raises USD83.5 Million in Series B Financing 101

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 103

NeuroVia Raises USD14 Million in Series A Financing 105

E-scape Bio Raises Additional USD8 Million in Series A Financing 106

Anaeropharma Science Raises USD13.2 Million in Venture Financing 108

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 109

ONL Therapeutics Raises USD4.2 Million in Series A Venture Financing 111

Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 112

Cavion Raises USD26 Million in Series A Financing 114

Inflazome Raises USD17 Million in Series A Financing 115

Rox Medical Raises USD40 Million in Series E Financing 116

Annexon Biosciences Raises USD44 Million in Series B Financing 117

IFM Therapeutics Raises USD27 Million in Series A Financing Round 118

F2G Raises USD60 Million in Venture Financing 119

Blade Therapeutics Raises USD27 Million in Series B Financing 121

Caribou Biosciences Raises USD30 Million in Series B Financing Round 123

Ideaya Biosciences Raises USD46 Million in Series A Financing 125

Rani Therapeutics Raises Funds in Financing 127

Galera Therapeutics Raises Additional USD5 Million in Series B Financing 129

Adicet Bio Raises USD51 Million in Series A Financing Round 130

C4 Therapeutics Raises USD73 Million in Series A Financing Round 131

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 132

Galera Therapeutics Raises USD37 Million in Series B Financing 134

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 135

Intellia Therapeutics Raises USD70 Million in Series B Financing 137

Merus Raises USD46.4 Million in First Tranche of Series C Financing 139

Encore Vision Raises USD2.5 Million in Series C Financing 141

E-scape Bio Raises USD55 Million in Series A Financing 142

Ra Pharma Raises USD58.5 Million in Series B Financing 144

Advanced Accelerator Applications Raises USD26 Million in Venture Financing 146

Kanyos Bio Raises USD16 Million in Venture Financing 147

Arcus Biosciences Raises USD50 Million in Series A Financing 148

Rani Therapeutics Raises USD25 Million in Series C Venture Financing 150

Innocrin Pharma Raises USD28 Million in Series D Financing 151

Nabriva Therapeutics Raises USD120 Million in Series B Financing 152

Caribou Biosciences Raises USD11 Million in Series A Financing 154

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 156

Neurovance Raises Additional USD5.5 Million in Venture Financing 157

Macrolide Pharma Raises USD22 Million in Series A Financing 158

Merganser Biotech Raises USD28 Million in Series A Financing 159

Vaxin Raises USD16 Million in Venture Financing 160

Surface Oncology Raises USD35 Million in Series A Financing 161

Annexon Bioscience Raises USD34 Million in Series A-1 Venture Financing 163

Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 164

Ziarco Raises USD33 Million in Series B Venture Financing 165

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 166

Quartet Medicine Raises USD17 Million in Series A Venture Financing 168

Innocrin Pharma Raises Funds through Venture Financing 169

Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 170

Viamet Pharma Raises USD60 Million in Series D Venture Financing 172

Raze Therapeutics Raises USD24 Million in Series A Venture Financing 173

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 175

Encore Vision Raises USD1.7 Million in Venture Financing 176

Neurovance Raises Additional USD4 Million in Venture Financing 177

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 178

Sorbent Therapeutics Raises USD6.5 Million In First Tranche Of Series D Financing 179

ImaginAb Raises USD21 Million in Series B Venture Financing 180

Anokion Raises USD 37.5 Million In Series A Venture financing 181

Aerpio Therapeutics Raises USD 22 Million In Venture Financing 182

Spinifex Pharma Raises USD6.2 Million in Venture Financing 184

Spinifex Pharma Raises USD 45 Million In Series C Financing 185

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 187

Thesan Pharma Raises USD 49 Million In Series B Venture Financing 188

Covagen Raises USD 50.3 Million In Series B Financing 189

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 191

Encore Vision Secures USD5 Million in Venture Funding 192

Aileron Therapeutics Raises USD 30 Million In Series E Financing 193

Aerpio Therapeutics Raises USD 9 Million In Extended Series A Financing 195

Merus Raises USD 42 Million In Extended Series B Financing 197

Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 199

Akebia Therapeutics Raises USD 41 Million In Series C Financing 201

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 202

Effector Therapeutics Raises USD 45 Million In Series A Financing 203

Tokai Pharma Raises USD 35.5 Million In Series E Financing 205

Neurovance Raises USD 6 Million In Series A1 Financing 206

GenSight Biologics Raises USD 41.6 Million In Series A Financing 208

Catalyst Biosciences Secures USD5.07 Million in Venture Funding 210

CoStim Pharma Raises USD 10 Million In Venture Financing 212

Aileron Raises USD 12 Million In Extended Series D Financing 213

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 215

Galera Therapeutics Raises USD 11 Million In Series A Financing 217

Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 218

Thesan Pharma Raises Additional USD 12 Million In Series A Financing 219

Qurient Raises USD 4 Million In Venture Financing 220

Selexys Pharma Raises USD 23 Million In Series A Financing 221

F2G Raises USD 30 Million In Venture Financing 222

Aerpio Therapeutics Raises USD 27 Million In Series A Financing 223

PharmAbcine Raises USD 3.5 Million In Series B Financing 224

Ra Pharma Raises USD 8.6 Million In Second Tranche Of Series A Financing 225

Celladon Raises Additional USD 10 Million In Series D Financing 226

BioRelix Raises USD 0.27 Million In Venture Financing 228

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 229

Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 230

AMP Therapeutics Raises Funds Through Series A Financing 231

Samara Capital Partners Acquires Anti-Infective Brands from Novartis 232

Gamida Cell Raises USD40 Million in Private Financing 233

Ampersand Capital Partners and 1315 Capital Acquires Genoptix 235

dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 236

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 237

Pfizer Enters into Co-Development Agreement with Novartis 238

Global Antibiotic Research & Development Partnership Enters into Partnership with Novartis 239

Novartis and Mundipharma Enter into Agreement 240

Novartis and Albumedix Enter into Agreement 241

Pear Therapeutics Enters into Agreement with Sandoz 242

Novartis to Enter into Agreement with Wyss Institute for Biologically Inspired Engineering at Harvard 243

Pear Therapeutics Enters into Agreement with Novartis 244

Novartis and Bill & Melinda Gates Foundation Enter into Partnership 245

Sandoz International Enters into Agreement with Biocon 246

Homology Medicines Enters into Agreement with Novartis 247

Novartis Enters into Agreement with University of California 248

Helsinn Therapeutics Enters into Co-Promotion Agreement with Novartis 249

Cipla and Novartis May Enter into Co-Marketing Agreement 250

Oxford BioMedica Enters into Agreement with Novartis 251

Bristol-Myers Squibb Enters into Partnership with Novartis 252

Allergan Enters into Agreement with Novartis 253

Perthera Enters into Agreement with Novartis 254

TARGET PharmaSolutions Enters into Agreement with Novartis 255

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 256

Protagen Enters into Agreement with Novartis Pharma 258

Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 259

Rovi Enters into Co-Marketing Agreement with Novartis for Neparvis 260

Cerulean Pharma Enters into Partnership with Novartis 261

Perlara Enters into Partnership with Novartis 262

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 263

Cure Forward Partners with Novartis Pharma 264

Novartis Expands its Agreement with Medicines for Malaria Venture 265

Novartis Pharma Enters into Agreement with Eisai 266

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 267

Cigna Enters into Contract with Novartis 268

MedinCell Enters into Agreement with Sandoz International 269

Radius Health Partners with Novartis Pharma for RAD1901 270

NeoBiocon Enters into Agreement with Novartis 271

Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 272

Amgen Expands its Co-Development Agreement with Novartis 273

Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 274

Novartis AG, Key Competitors 506

Novartis AG, Key Employees 507

Novartis AG, Subsidiaries 509

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Novartis AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG (NOVN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 13

List of Figures 19

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Novartis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25

Novartis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27

Novartis AG, Pharmaceuticals & Healthcare, Deal Details 62

Asset Purchase 62

Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 62

Fougera Pharma Acquires US Rights to Veregen from Medigene 63

Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 64

Sandoz Acquires Product Portfolio of Euro-Pharm International Canada 66

Novartis Acquires Rights to Interleukin-17 from Ensemble Therapeutics 67

Novartis Acquires Rights of PF-06438179 from Pfizer 68

Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 69

Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 70

Teva Pharma May Divest its Assets 71

Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 73

Novartis Pharma Acquires Immunotherapy Manufacturing Facility From Dendreon For USD 43 Million 75

SensoMotoric Sells Ophthalmic Division To Alcon Labs 76

Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 77

Venture Financing 78

Galera Therapeutics Raises USD70 Million in Series C Venture Financing 78

Coda Biotherapeutics Raises USD19 Million in Series A Financing 80

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 81

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 83

Akouos Raises USD50 Million in Series A Financing 85

Enterprise Therapeutics Raises USD41.1 Million in Series B Venture Financing 87

Oculis Raises USD20.51 Million in Series B Financing 89

Expansion Therapeutics Raises USD55.3 Million in Series A Financing 91

Semma Therapeutics Raises USD114 Million in Series B Financing 93

Perlara Raises USD7.4 Million in Venture Financing 95

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 96

ImaginAb Raises USD7.7 Million in Venture Financing 98

Rani Therapeutics Raises USD39 Million in Series D Financing 99

Homology Medicines Raises USD83.5 Million in Series B Financing 101

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 103

NeuroVia Raises USD14 Million in Series A Financing 105

E-scape Bio Raises Additional USD8 Million in Series A Financing 106

Anaeropharma Science Raises USD13.2 Million in Venture Financing 108

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 109

ONL Therapeutics Raises USD4.2 Million in Series A Venture Financing 111

Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 112

Cavion Raises USD26 Million in Series A Financing 114

Inflazome Raises USD17 Million in Series A Financing 115

Rox Medical Raises USD40 Million in Series E Financing 116

Annexon Biosciences Raises USD44 Million in Series B Financing 117

IFM Therapeutics Raises USD27 Million in Series A Financing Round 118

F2G Raises USD60 Million in Venture Financing 119

Blade Therapeutics Raises USD27 Million in Series B Financing 121

Caribou Biosciences Raises USD30 Million in Series B Financing Round 123

Ideaya Biosciences Raises USD46 Million in Series A Financing 125

Rani Therapeutics Raises Funds in Financing 127

Galera Therapeutics Raises Additional USD5 Million in Series B Financing 129

Adicet Bio Raises USD51 Million in Series A Financing Round 130

C4 Therapeutics Raises USD73 Million in Series A Financing Round 131

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 132

Galera Therapeutics Raises USD37 Million in Series B Financing 134

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 135

Intellia Therapeutics Raises USD70 Million in Series B Financing 137

Merus Raises USD46.4 Million in First Tranche of Series C Financing 139

Encore Vision Raises USD2.5 Million in Series C Financing 141

E-scape Bio Raises USD55 Million in Series A Financing 142

Ra Pharma Raises USD58.5 Million in Series B Financing 144

Advanced Accelerator Applications Raises USD26 Million in Venture Financing 146

Kanyos Bio Raises USD16 Million in Venture Financing 147

Arcus Biosciences Raises USD50 Million in Series A Financing 148

Rani Therapeutics Raises USD25 Million in Series C Venture Financing 150

Innocrin Pharma Raises USD28 Million in Series D Financing 151

Nabriva Therapeutics Raises USD120 Million in Series B Financing 152

Caribou Biosciences Raises USD11 Million in Series A Financing 154

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 156

Neurovance Raises Additional USD5.5 Million in Venture Financing 157

Macrolide Pharma Raises USD22 Million in Series A Financing 158

Merganser Biotech Raises USD28 Million in Series A Financing 159

Vaxin Raises USD16 Million in Venture Financing 160

Surface Oncology Raises USD35 Million in Series A Financing 161

Annexon Bioscience Raises USD34 Million in Series A-1 Venture Financing 163

Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 164

Ziarco Raises USD33 Million in Series B Venture Financing 165

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 166

Quartet Medicine Raises USD17 Million in Series A Venture Financing 168

Innocrin Pharma Raises Funds through Venture Financing 169

Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 170

Viamet Pharma Raises USD60 Million in Series D Venture Financing 172

Raze Therapeutics Raises USD24 Million in Series A Venture Financing 173

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 175

Encore Vision Raises USD1.7 Million in Venture Financing 176

Neurovance Raises Additional USD4 Million in Venture Financing 177

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 178

Sorbent Therapeutics Raises USD6.5 Million In First Tranche Of Series D Financing 179

ImaginAb Raises USD21 Million in Series B Venture Financing 180

Anokion Raises USD 37.5 Million In Series A Venture financing 181

Aerpio Therapeutics Raises USD 22 Million In Venture Financing 182

Spinifex Pharma Raises USD6.2 Million in Venture Financing 184

Spinifex Pharma Raises USD 45 Million In Series C Financing 185

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 187

Thesan Pharma Raises USD 49 Million In Series B Venture Financing 188

Covagen Raises USD 50.3 Million In Series B Financing 189

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 191

Encore Vision Secures USD5 Million in Venture Funding 192

Aileron Therapeutics Raises USD 30 Million In Series E Financing 193

Aerpio Therapeutics Raises USD 9 Million In Extended Series A Financing 195

Merus Raises USD 42 Million In Extended Series B Financing 197

Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 199

Akebia Therapeutics Raises USD 41 Million In Series C Financing 201

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 202

Effector Therapeutics Raises USD 45 Million In Series A Financing 203

Tokai Pharma Raises USD 35.5 Million In Series E Financing 205

Neurovance Raises USD 6 Million In Series A1 Financing 206

GenSight Biologics Raises USD 41.6 Million In Series A Financing 208

Catalyst Biosciences Secures USD5.07 Million in Venture Funding 210

CoStim Pharma Raises USD 10 Million In Venture Financing 212

Aileron Raises USD 12 Million In Extended Series D Financing 213

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 215

Galera Therapeutics Raises USD 11 Million In Series A Financing 217

Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 218

Thesan Pharma Raises Additional USD 12 Million In Series A Financing 219

Qurient Raises USD 4 Million In Venture Financing 220

Selexys Pharma Raises USD 23 Million In Series A Financing 221

F2G Raises USD 30 Million In Venture Financing 222

Aerpio Therapeutics Raises USD 27 Million In Series A Financing 223

PharmAbcine Raises USD 3.5 Million In Series B Financing 224

Ra Pharma Raises USD 8.6 Million In Second Tranche Of Series A Financing 225

Celladon Raises Additional USD 10 Million In Series D Financing 226

BioRelix Raises USD 0.27 Million In Venture Financing 228

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 229

Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 230

AMP Therapeutics Raises Funds Through Series A Financing 231

Private Equity 232

Samara Capital Partners Acquires Anti-Infective Brands from Novartis 232

Gamida Cell Raises USD40 Million in Private Financing 233

Ampersand Capital Partners and 1315 Capital Acquires Genoptix 235

dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 236

Partnerships 237

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 237

Pfizer Enters into Co-Development Agreement with Novartis 238

Global Antibiotic Research & Development Partnership Enters into Partnership with Novartis 239

Novartis and Mundipharma Enter into Agreement 240

Novartis and Albumedix Enter into Agreement 241

Pear Therapeutics Enters into Agreement with Sandoz 242

Novartis to Enter into Agreement with Wyss Institute for Biologically Inspired Engineering at Harvard 243

Pear Therapeutics Enters into Agreement with Novartis 244

Novartis and Bill & Melinda Gates Foundation Enter into Partnership 245

Sandoz International Enters into Agreement with Biocon 246

Homology Medicines Enters into Agreement with Novartis 247

Novartis Enters into Agreement with University of California 248

Helsinn Therapeutics Enters into Co-Promotion Agreement with Novartis 249

Cipla and Novartis May Enter into Co-Marketing Agreement 250

Oxford BioMedica Enters into Agreement with Novartis 251

Bristol-Myers Squibb Enters into Partnership with Novartis 252

Allergan Enters into Agreement with Novartis 253

Perthera Enters into Agreement with Novartis 254

TARGET PharmaSolutions Enters into Agreement with Novartis 255

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 256

Protagen Enters into Agreement with Novartis Pharma 258

Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 259

Rovi Enters into Co-Marketing Agreement with Novartis for Neparvis 260

Cerulean Pharma Enters into Partnership with Novartis 261

Perlara Enters into Partnership with Novartis 262

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 263

Cure Forward Partners with Novartis Pharma 264

Novartis Expands its Agreement with Medicines for Malaria Venture 265

Novartis Pharma Enters into Agreement with Eisai 266

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 267

Cigna Enters into Contract with Novartis 268

MedinCell Enters into Agreement with Sandoz International 269

Radius Health Partners with Novartis Pharma for RAD1901 270

NeoBiocon Enters into Agreement with Novartis 271

Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 272

Amgen Expands its Co-Development Agreement with Novartis 273

Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 274

Sosei Plans to Enter into Agreement with Novartis 275

Rani Therapeutics Enters into Agreement with Novartis 276

PaxVax Enters into Distribution Agreement with Novartis 277

Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 278

Semma Therapeutics Enters into Agreement with Novartis 279

Novartis Enters into Co-Development Agreement with Department of Science & Technology 280

PeptiDream Expands Drug Discovery Agreement with Novartis 281

BioLineRx Enters into Agreement with Novartis Pharma 282

Rega Institute for Medical Research, Centre for Drug Design and Discovery, KRICT Enters into Partnership with Novartis 283

Novartis Enters into Licensing Agreement with Ligand Pharma 334

Novartis AG - Key Competitors 506

Novartis AG - Key Employees 507

Novartis AG - Locations And Subsidiaries 509

Head Office 509

Other Locations & Subsidiaries 509

Recent Developments 527

Strategy And Business Planning 527

Oct 30, 2018: Novartis and Pfizer partner to advance NASH therapy 527

Oct 04, 2018: Novartis licences anti-infective candidates to Boston Pharmaceuticals 528

Sep 28, 2018: Novartis signs Chinese manufacturing deal with Cellular Biomedicines for Kymriah 529

Sep 25, 2018: Novartis to cut more than 2000 jobs in Switzerland and UK 530

Sep 25, 2018: Novartis proposes to exit Grimsby UK site by end of 2020 as part of global manufacturing network transformation 531

Sep 11, 2018: Nova Medical Centers opens occupational medicine clinic in El Paso, Texas 532

Sep 06, 2018: Novartis to divest select Sandoz US portfolio to Aurobindo for $900m 533

Jul 02, 2018: Novartis plans to spin-off eye care unit into standalone entity 534

Oct 16, 2017: Novartis to Shut Broomfield Generics Manufacturing Unit, Eliminate 450 Jobs 535

Financial Announcements 536

Oct 18, 2018: Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth 536

Jul 18, 2018: Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company 541

Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 546

Jan 24, 2018: Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase 550

Oct 24, 2017: Novartis delivered growth on top and bottom line in all divisions in Q3 558

Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 563

Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 568

Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 572

Corporate Communications 578

Aug 14, 2018: Novartis names Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer 578

May 16, 2018: Novartis announces changes to the Executive Committee 579

Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 580

Mar 19, 2018: Novartis Foundation joins Global Partnership for Zero Leprosy 581

Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 582

Dec 15, 2017: Novartis announces Oncology head to retire 583


List Of Figure

List of Figures

Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21

Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25


List Of Table

List of Tables

Novartis AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Novartis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Novartis AG, Deals By Therapy Area, 2012 to YTD 2018 23

Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25

Novartis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27

Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 62

Fougera Pharma Acquires US Rights to Veregen from Medigene 63

Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 64

Sandoz Acquires Product Portfolio of Euro-Pharm International Canada 66

Novartis Acquires Rights to Interleukin-17 from Ensemble Therapeutics 67

Novartis Acquires Rights of PF-06438179 from Pfizer 68

Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 69

Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 70

Teva Pharma May Divest its Assets 71

Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 73

Novartis Pharma Acquires Immunotherapy Manufacturing Facility From Dendreon For USD 43 Million 75

SensoMotoric Sells Ophthalmic Division To Alcon Labs 76

Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 77

Galera Therapeutics Raises USD70 Million in Series C Venture Financing 78

Coda Biotherapeutics Raises USD19 Million in Series A Financing 80

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 81

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 83

Akouos Raises USD50 Million in Series A Financing 85

Enterprise Therapeutics Raises USD41.1 Million in Series B Venture Financing 87

Oculis Raises USD20.51 Million in Series B Financing 89

Expansion Therapeutics Raises USD55.3 Million in Series A Financing 91

Semma Therapeutics Raises USD114 Million in Series B Financing 93

Perlara Raises USD7.4 Million in Venture Financing 95

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 96

ImaginAb Raises USD7.7 Million in Venture Financing 98

Rani Therapeutics Raises USD39 Million in Series D Financing 99

Homology Medicines Raises USD83.5 Million in Series B Financing 101

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 103

NeuroVia Raises USD14 Million in Series A Financing 105

E-scape Bio Raises Additional USD8 Million in Series A Financing 106

Anaeropharma Science Raises USD13.2 Million in Venture Financing 108

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 109

ONL Therapeutics Raises USD4.2 Million in Series A Venture Financing 111

Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 112

Cavion Raises USD26 Million in Series A Financing 114

Inflazome Raises USD17 Million in Series A Financing 115

Rox Medical Raises USD40 Million in Series E Financing 116

Annexon Biosciences Raises USD44 Million in Series B Financing 117

IFM Therapeutics Raises USD27 Million in Series A Financing Round 118

F2G Raises USD60 Million in Venture Financing 119

Blade Therapeutics Raises USD27 Million in Series B Financing 121

Caribou Biosciences Raises USD30 Million in Series B Financing Round 123

Ideaya Biosciences Raises USD46 Million in Series A Financing 125

Rani Therapeutics Raises Funds in Financing 127

Galera Therapeutics Raises Additional USD5 Million in Series B Financing 129

Adicet Bio Raises USD51 Million in Series A Financing Round 130

C4 Therapeutics Raises USD73 Million in Series A Financing Round 131

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 132

Galera Therapeutics Raises USD37 Million in Series B Financing 134

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 135

Intellia Therapeutics Raises USD70 Million in Series B Financing 137

Merus Raises USD46.4 Million in First Tranche of Series C Financing 139

Encore Vision Raises USD2.5 Million in Series C Financing 141

E-scape Bio Raises USD55 Million in Series A Financing 142

Ra Pharma Raises USD58.5 Million in Series B Financing 144

Advanced Accelerator Applications Raises USD26 Million in Venture Financing 146

Kanyos Bio Raises USD16 Million in Venture Financing 147

Arcus Biosciences Raises USD50 Million in Series A Financing 148

Rani Therapeutics Raises USD25 Million in Series C Venture Financing 150

Innocrin Pharma Raises USD28 Million in Series D Financing 151

Nabriva Therapeutics Raises USD120 Million in Series B Financing 152

Caribou Biosciences Raises USD11 Million in Series A Financing 154

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 156

Neurovance Raises Additional USD5.5 Million in Venture Financing 157

Macrolide Pharma Raises USD22 Million in Series A Financing 158

Merganser Biotech Raises USD28 Million in Series A Financing 159

Vaxin Raises USD16 Million in Venture Financing 160

Surface Oncology Raises USD35 Million in Series A Financing 161

Annexon Bioscience Raises USD34 Million in Series A-1 Venture Financing 163

Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 164

Ziarco Raises USD33 Million in Series B Venture Financing 165

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 166

Quartet Medicine Raises USD17 Million in Series A Venture Financing 168

Innocrin Pharma Raises Funds through Venture Financing 169

Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 170

Viamet Pharma Raises USD60 Million in Series D Venture Financing 172

Raze Therapeutics Raises USD24 Million in Series A Venture Financing 173

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 175

Encore Vision Raises USD1.7 Million in Venture Financing 176

Neurovance Raises Additional USD4 Million in Venture Financing 177

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 178

Sorbent Therapeutics Raises USD6.5 Million In First Tranche Of Series D Financing 179

ImaginAb Raises USD21 Million in Series B Venture Financing 180

Anokion Raises USD 37.5 Million In Series A Venture financing 181

Aerpio Therapeutics Raises USD 22 Million In Venture Financing 182

Spinifex Pharma Raises USD6.2 Million in Venture Financing 184

Spinifex Pharma Raises USD 45 Million In Series C Financing 185

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 187

Thesan Pharma Raises USD 49 Million In Series B Venture Financing 188

Covagen Raises USD 50.3 Million In Series B Financing 189

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 191

Encore Vision Secures USD5 Million in Venture Funding 192

Aileron Therapeutics Raises USD 30 Million In Series E Financing 193

Aerpio Therapeutics Raises USD 9 Million In Extended Series A Financing 195

Merus Raises USD 42 Million In Extended Series B Financing 197

Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 199

Akebia Therapeutics Raises USD 41 Million In Series C Financing 201

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 202

Effector Therapeutics Raises USD 45 Million In Series A Financing 203

Tokai Pharma Raises USD 35.5 Million In Series E Financing 205

Neurovance Raises USD 6 Million In Series A1 Financing 206

GenSight Biologics Raises USD 41.6 Million In Series A Financing 208

Catalyst Biosciences Secures USD5.07 Million in Venture Funding 210

CoStim Pharma Raises USD 10 Million In Venture Financing 212

Aileron Raises USD 12 Million In Extended Series D Financing 213

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 215

Galera Therapeutics Raises USD 11 Million In Series A Financing 217

Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 218

Thesan Pharma Raises Additional USD 12 Million In Series A Financing 219

Qurient Raises USD 4 Million In Venture Financing 220

Selexys Pharma Raises USD 23 Million In Series A Financing 221

F2G Raises USD 30 Million In Venture Financing 222

Aerpio Therapeutics Raises USD 27 Million In Series A Financing 223

PharmAbcine Raises USD 3.5 Million In Series B Financing 224

Ra Pharma Raises USD 8.6 Million In Second Tranche Of Series A Financing 225

Celladon Raises Additional USD 10 Million In Series D Financing 226

BioRelix Raises USD 0.27 Million In Venture Financing 228

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 229

Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 230

AMP Therapeutics Raises Funds Through Series A Financing 231

Samara Capital Partners Acquires Anti-Infective Brands from Novartis 232

Gamida Cell Raises USD40 Million in Private Financing 233

Ampersand Capital Partners and 1315 Capital Acquires Genoptix 235

dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 236

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 237

Pfizer Enters into Co-Development Agreement with Novartis 238

Global Antibiotic Research & Development Partnership Enters into Partnership with Novartis 239

Novartis and Mundipharma Enter into Agreement 240

Novartis and Albumedix Enter into Agreement 241

Pear Therapeutics Enters into Agreement with Sandoz 242

Novartis to Enter into Agreement with Wyss Institute for Biologically Inspired Engineering at Harvard 243

Pear Therapeutics Enters into Agreement with Novartis 244

Novartis and Bill & Melinda Gates Foundation Enter into Partnership 245

Sandoz International Enters into Agreement with Biocon 246

Homology Medicines Enters into Agreement with Novartis 247

Novartis Enters into Agreement with University of California 248

Helsinn Therapeutics Enters into Co-Promotion Agreement with Novartis 249

Cipla and Novartis May Enter into Co-Marketing Agreement 250

Oxford BioMedica Enters into Agreement with Novartis 251

Bristol-Myers Squibb Enters into Partnership with Novartis 252

Allergan Enters into Agreement with Novartis 253

Perthera Enters into Agreement with Novartis 254

TARGET PharmaSolutions Enters into Agreement with Novartis 255

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 256

Protagen Enters into Agreement with Novartis Pharma 258

Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 259

Rovi Enters into Co-Marketing Agreement with Novartis for Neparvis 260

Cerulean Pharma Enters into Partnership with Novartis 261

Perlara Enters into Partnership with Novartis 262

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 263

Cure Forward Partners with Novartis Pharma 264

Novartis Expands its Agreement with Medicines for Malaria Venture 265

Novartis Pharma Enters into Agreement with Eisai 266

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 267

Cigna Enters into Contract with Novartis 268

MedinCell Enters into Agreement with Sandoz International 269

Radius Health Partners with Novartis Pharma for RAD1901 270

NeoBiocon Enters into Agreement with Novartis 271

Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 272

Amgen Expands its Co-Development Agreement with Novartis 273

Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 274

Novartis AG, Key Competitors 506

Novartis AG, Key Employees 507

Novartis AG, Subsidiaries 509

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Novartis AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.